FUNDED RESEARCH
R01 CA136387-06 Title: Interplay Between KSHV and PDGFRA in AIDS-Kaposi's Sarcoma Oncogenesis Role: Co-P.I.s: Enrique A. Mesri; Funding: $2,286,115
Individualized Risk Stratification Using the Genomic Contribution; NIH/NHLBI #: 1R01HL102487;Role: Co-Investigator (3%); P.I. Gary W. Beecham and David M. Seo; Total Direct Cost: $2,449,847
Advance Partnerships for Adaptation, Implementation, and Dissemination (PAID) Award: Scientists and Engineers Expanding Diversity and Success (SEEDS) at the University of Miami National Science Foundation (NSF); HRD-0820128; Kathryn W. Tosney (P.I.); Total: $543,441
Ryan White Title I Health and Support Services for Persons Living with HIV/AIDS REP#0307; Miami-Dade County; Role: P.I.; Total Direct Cost: $3,319,786
Impact of Aging on Stem Repair in Atherosclerosis; 5R01 AG023073-01A1Role: P.I. (10%); Total Direct Cost: $1,216,654
The Genetics of Biobehavioral Risk Factors for CVD;HL36587; Role: Project 1 – Consultant; Core C
Progenitor Cell Based Therapeutic Strategies for Atherosclerosis Doris Duke Clinical Interfaces Award; Total Direct Cost: $80,000
Angiogenesis and Mechanisms of Exercise Training in PAD HL075752-01; Role: Consultant
GENECARD: Gene Identification in Early-Onset CAD HL073389-02; Role: Consultant
Mentored Clinical Research Scholar Program; RR17630-03; Role: Mentor
A Comparative Approach to Genomics of Complex Traits P01 HL73042/HG02384; Role: P.I.; Total Direct Cost: $14 million
General Clinical Research Center; NIH# M01 RR16587; Role: P.I. (5%)
Title: Rac, Superoxide and Antioxidants in Hypertension 5R01 HL71536; Role: P.I. (15%)
Medtronic - Duke Cardiovascular Strategic Alliance to Improve Human Welfare Medusa – Medtronic; Role: P.I.
Title: Dynamics of Flow-Dependent Arterial Permeability NIH#: R0-1 HL50442Role: Co-Investigator (10%); (P.I.: M. Friedman)
Field: Endothelial cell dysfunction, growth factors and vasoactive mediators in accelerated graft arteriosclerosis; Endothelial cell dysfunctional apoptosis in AGA; Sandoz Pharmaceutical; Role: P.I. (20%)
Field: Integrins, polymorphisms, thrombosis and pharmacogenetics Title: Platelet PLA2: studies on a pro-thrombotic polymorphism NIH#: R0-1 DK57488; Role: Co-Investigator (10%); Paul F. Bray (P.I.)
Title: Tyrosine kinase signaling pathway in post-ischemic inflammation American Heart Association Established Investigator Award AHA#: 0 95002600; Role: P.I.
Field: Organization and regulation of actin cytoskeleton Title: Profilin I: an essential protein in cells and animals (Renewed as HL71536) NIH#: GM053236; Role: P.I. (20%)
Field: Endothelial cell dysfunction, growth factors and vasoactive mediators in accelerated graft arteriosclerosis; Endothelial cell dysfunctional apoptosis in AGA Sandoz Pharmaceutical; Role: P.I. (5%)
Field: Cell signaling in post-ischemic inflammation SCOR-project title: Tyrosine kinase signaling pathway in post-ischemic inflammation NIH#: P50 HL52315; Role: P.I. (50%)
Field: Systemic Sclerosis: Molecular mechanisms underlying vascular cell abnormalities and intimal lesion formation in scleroderma
Emphasis: TGF-β and Smads; Scleroderma Research Foundation; Role: P.I.
ADDITIONAL PAST GRANTS:
Syntex Scholars Program Award; The control of cell motility by receptor tyrosine kinase; Role: P.I.
AHA-Grant-In-Aid; The control of cell shape by receptor tyrosine kinase; Role: P.I.
Clinician Scientist Award; Tyrosine phosphorylation of phospholipase C and cytoskeleton reorganization; Role: P.I.
NIH STUDY SECTION:
06/17/2002 – 06/18/2002 Experimental Cardiovascular Sciences Study Section
06/16/2003 – 06/17/2003 Experimental Cardiovascular Sciences Study Section
07/01/2003 – 12/31/2003 Experimental Cardiovascular Sciences Study Section
10/17/2003 – 03/08/2006 Atherosclerosis and Inflammation of the Cardiovascular System Study Section
OTHER NIH SERVICE:
11/03/1998 – 11/04/1998 National Heart, Lung, and Blood Institute Special Emphasis Panel
11/21/2000 – 11/21/2000 Center for Scientific Review Special Emphasis Panel
10/11/2002 – 10/11/2002 National Heart, Lung, and Blood Institute Special Emphasis Panel
05/14/2012 – 05/15/2012 National Heart, Lung and Blood Institute – Board of Scientific Counselors Review
PATENTS AWARDED
Expression Analysis of Coronary Artery Atherosclerosis (with David Seo, patent #2011/0287961 A1; issued 11/24/11)
Rac-Like Genes and Methods of Use (Jonathan Duvick, Pioneer Hi Bred, patent # WO0015800)
Use of Platelet Polymorphism PIA2 to Diagnose Risk of Thrombotic Disease (patent #5955266, issued 9/21/99)
Microtubule Binding to Smads Regulates TGF-beta Activity
Use of Plant Rac Isoforms for Human Applications
Gene Therapy (SfasR) (Novartis, patent # WO0063369)
Fas-Null Pigs for Xenotransplantation
Atherosclerotic Phenotype Determinative Genes and Methods for Using the Same (Nevins, Patent #WO20030913, 11/06/03)
Stem Cell Therapy for the Prevention of Atherosclerosis and Related Ailments
Use of EASD Technology for Intervention on Blood Vessels and Other Cardiovascular Structures
Use and Detection of Stem Cell Carriers to Deliver Nano- and Micro-Devices to the Vessel Wall
Use of the Exo-Arterial Snake Device (CASD) Technique
Induction of CD133+/CD34+ Cell Proliferation and Differentiation
Discovery of Simple Little Cells
Novel Technology to Assess with Unprecedented Accuracy the Impact of Drugs and Small Molecules onAtherosclerosis and Related Complications
Molecular Signature for Arterial Repair by Progenitor Cells, Discovery of New Markers and Targets for Cardiovascular Disease
Progenitor Cells and Methods of Using Same (Goldschmidt, 11/4/2004, patent # 2004078927)
Atherosclerosis (with Chunming Dong, 4/24/08, patent #20080095751 A1)
Pretreatment of bone marrow derived stem cells to improve reparative capability (in process with David Seo)
Method of inhibiting atherosclerotic plaque destabilization (Goldschmidt, 7/4/2003, app# 20030138857)
Atherosclerotic phenotype determinative genes and methods for using the same (West, 12/4/2003, app # 20030224383)
Tumors that are indistinguishable from Kaposi Sarcoma (with Qi Ma)
Methods and compositions for correlating genetic markers with cardiovascular disease (Jeff Vance, 10/27/05, app # 20060115845; App 11/260842)
Atherosclerotic phenotype determinative genes and methods for using the same (West, 03/09/06, patent # WO20060260)
LSAMP Gene Associated with Cardiovascular Disease (with Jeff Vance, app date: 07/08/2007, application number 20070148661; 11/458228)
Methods of determining the risk of developing coronary artery disease (Hauser, Duke University, patent # WO20070869)
Pretreatment of bone marrow derived cells to improve their ability to repair vascular tissues (Xiaohua Song and David Seo, UMJ-127, December 22, 2009)
Genomic Phenotype of Coronary Artery Atherosclerosis (David Seo, Jennifer Clarke, Provisional Application, Atty Docket: 29532-248511, October 14, 2008)